Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Director John W. Kozarich sold 5,000 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $141.71, for a total transaction of $708,550.00. Following the transaction, the director now directly owns 35,649 shares of the company’s stock, valued at approximately $5,051,819.79. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Ligand Pharmaceuticals Incorporated (LGND) traded down $1.40 during midday trading on Friday, reaching $140.31. The company’s stock had a trading volume of 251,757 shares, compared to its average volume of 248,087. The stock has a market cap of $3,061.77, a PE ratio of 109.07, a PEG ratio of 2.24 and a beta of 0.94. Ligand Pharmaceuticals Incorporated has a 52-week low of $95.08 and a 52-week high of $149.31. The company has a debt-to-equity ratio of 0.05, a quick ratio of 0.95 and a current ratio of 0.97.

Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.69 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.32. The firm had revenue of $33.38 million during the quarter, compared to analysts’ expectations of $31.04 million. Ligand Pharmaceuticals had a return on equity of 7.83% and a net margin of 12.76%. Ligand Pharmaceuticals’s quarterly revenue was up 54.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.62 EPS. equities analysts anticipate that Ligand Pharmaceuticals Incorporated will post 2.35 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Ligand Pharmaceuticals Incorporated (LGND) Director John W. Kozarich Sells 5,000 Shares” was originally reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/11/17/ligand-pharmaceuticals-incorporated-lgnd-director-john-w-kozarich-sells-5000-shares.html.

A number of research firms recently issued reports on LGND. Craig Hallum reissued a “buy” rating and set a $170.00 target price (up previously from $160.00) on shares of Ligand Pharmaceuticals in a research report on Wednesday. HC Wainwright set a $159.00 target price on shares of Ligand Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday. Roth Capital set a $158.00 target price on shares of Ligand Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday. Zacks Investment Research raised shares of Ligand Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $165.00 target price for the company in a research report on Thursday, October 12th. Finally, ValuEngine raised shares of Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 10th. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Ligand Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $148.83.

Several institutional investors have recently added to or reduced their stakes in the company. Coe Capital Management LLC purchased a new position in shares of Ligand Pharmaceuticals during the 3rd quarter valued at approximately $948,000. Piedmont Investment Advisors LLC boosted its stake in shares of Ligand Pharmaceuticals by 10.7% during the 3rd quarter. Piedmont Investment Advisors LLC now owns 4,556 shares of the biotechnology company’s stock valued at $620,000 after buying an additional 440 shares during the last quarter. California Public Employees Retirement System boosted its stake in shares of Ligand Pharmaceuticals by 5.2% during the 3rd quarter. California Public Employees Retirement System now owns 41,449 shares of the biotechnology company’s stock valued at $5,643,000 after buying an additional 2,049 shares during the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of Ligand Pharmaceuticals during the 3rd quarter valued at approximately $3,857,000. Finally, Granahan Investment Management Inc. MA boosted its stake in shares of Ligand Pharmaceuticals by 8.0% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 35,272 shares of the biotechnology company’s stock valued at $4,802,000 after buying an additional 2,602 shares during the last quarter.

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.